Zepbound results in more weight loss than Wegovy in trial, Eli Lilly says
People who took Zepbound, Eli Lilly’s weight loss drug, shed more pounds than those on Novo Nordisk’s Wegovy in a clinical trial, Lilly said in a release Wednesday.
People who took Zepbound, Eli Lilly’s weight loss drug, shed more pounds than those on Novo Nordisk’s Wegovy in a head-to-head clinical trial, Lilly said in a news release Wednesday.
The study, which Lilly funded, is the first randomized, controlled clinical trial comparing the two rival weight loss drugs. Previous studies have shown Zepbound outperforms Wegovy for weight loss, however, those weren’t considered true comparisons as they relied on looking back at existing data.
According to Lilly’s trial results, patients who got weekly injections of Zepbound lost an average 20.2% of their body weight, or 50.3 pounds, after 72 weeks, compared with an average of 13.7% body weight, or 33.1 pounds, for those who got Wegovy.
That means, Lilly says, Zepbound provides 47% more weight loss than Wegovy.
Dr. Susan Spratt, an endocrinologist and senior medical director for the Population Health Management Office at Duke Health in North Carolina, said that although Zepbound provided more weight loss than Wegovy, both drugs are highly effective.
Rating: 5